Ginkgo Bioworks Holdings, Inc. (DNA)
$11.76-0.25%Close
BUYCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $768M
- Beta
- 1.79
- P/E (TTM)
- -2.34
- Short % float
- 15.29%
- Days to cover
- 2.7
- SI change
- +2.1%
- 1W
- -5.24%
- 1M
- +67.76%
- vs SPY 1W
- -5.10%
- vs SPY 1M
- +65.25%
Industry peers
FMP comparable companies · ranked by market cap
- IOVABUYIovance Biotherapeutics, Inc.$6.5BRECOVERYQ 9$14.62-0.41%
- MBXSELLMBX Biosciences, Inc. Common Stock$2.5BCRISISQ 36$53.24-5.81%
- MRVISELLMaravai LifeSciences Holdings, Inc.$2.1BCRISISQ -2$7.44-7.51%
- VIRBUYVir Biotechnology, Inc.$2.0BRECOVERYQ 12$11.70-6.11%
- REPLSELLReplimune Group, Inc.$1.1BCRISISQ 13$13.42-7.35%
- MGTXSELLMeiraGTx Holdings plc$990MCRISISQ 6$10.69-4.24%
- AVBPSELLArriVent BioPharma, Inc.$779MCRISISQ -6$16.73-2.25%
- ATXSAstria Therapeutics, Inc.$718M$12.58
- VALNSELLValneva SE$548MCRISISQ -1$5.78-6.24%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on DNA?
- LOPJLB’s latest quantitative signal on Ginkgo Bioworks Holdings, Inc. (DNA) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is DNA in?
- Ginkgo Bioworks Holdings, Inc. (DNA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Ginkgo Bioworks Holdings, Inc. (DNA) do?
- Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artif…